Show simple item record

dc.contributor.authorAndrews, Katherine T
dc.contributor.authorTran, Thanh N
dc.contributor.authorFairlie, David P
dc.date.accessioned2017-05-03T11:45:16Z
dc.date.available2017-05-03T11:45:16Z
dc.date.issued2012
dc.date.modified2013-06-07T04:36:15Z
dc.identifier.issn1381-6128
dc.identifier.doi10.2174/138161212801327257
dc.identifier.urihttp://hdl.handle.net/10072/48206
dc.description.abstractHistone deacetylases (HDACs) are important enzymes that effect post-translational modifications of proteins by altering the acetylation state of lysine residues. HDACs control epigenetic changes that trigger cell transformation and proliferation of transformed cells associated with many diseases. These enzymes are validated drug targets for some types of cancer and are promising therapeutic targets for a range of other diseases, including malaria. Annually, there are ~500 million clinical cases of malaria and ~0.8-1.2 million deaths. There is no licensed vaccine for preventing malaria, and parasites that cause malaria are becoming resistant to current drugs, necessitating the search for new therapies. HDAC inhibitors are emerging as a promising new class of antimalarial drugs with potent and selective action against Plasmodium parasites in vitro. Recent studies on the effects of HDAC inhibitors on the growth and development of P. falciparum have provided important new information on transcriptional regulation in malaria parasites and have validated the potential of this class of inhibitors for malaria therapy. To realise effective HDAC inhibitors for clinical trials, next generation inhibitors must not inhibit other human HDACs or proteins required for normal human physiology, be highly selective in killing parasites in vivo without killing normal host cells, and have improved bioavailability and pharmacokinetic profiles. This review summarizes current knowledge about malaria parasite HDACs and HDAC inhibitors with antimalarial properties, and provides insights for their development into new drugs for treatment of malaria.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherBentham Science Publishers Ltd.
dc.publisher.placeNetherlands
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom3467
dc.relation.ispartofpageto3479
dc.relation.ispartofissue24
dc.relation.ispartofjournalCurrent Pharmaceutical Design
dc.relation.ispartofvolume18
dc.rights.retentionY
dc.subject.fieldofresearchInfectious agents
dc.subject.fieldofresearchPharmacology and pharmaceutical sciences
dc.subject.fieldofresearchcode310702
dc.subject.fieldofresearchcode3214
dc.titleTowards Histone Deacetylase Inhibitors as New Antimalarial Drugs
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
gro.facultyGriffith Sciences, School of Natural Sciences
gro.date.issued2012
gro.hasfulltextNo Full Text
gro.griffith.authorAndrews, Katherine T.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record